By: Mehdia Amini, MD
New research explores the relationship between estrogen, metabolism, and the effectiveness of weight-loss medications.
For many women, weight management becomes increasingly challenging during perimenopause and menopause. Even without significant changes in diet or exercise, women may notice gradual weight gain, increasing abdominal fat, or changes in their overall body shape.
With the growing use of medications such as semaglutide (Wegovy) and tirzepatide (Zepbound), researchers are exploring an important question: Could menopausal hormone therapy influence how effectively women respond to these treatments?
What Does the Latest Research Show?
A large study presented at The Menopause Society’s Annual Meeting in October 2026 evaluated nearly 3,900 women receiving semaglutide or tirzepatide for weight management (Hormone Therapy May Increase Weight Loss Effectiveness of GLP-1s, 2026).
Among approximately 2,400 women receiving semaglutide, those also using menopausal hormone therapy experienced greater and more sustained weight loss compared with women taking semaglutide without hormone therapy.
Interestingly, the findings were less consistent with tirzepatide. Although women receiving hormone therapy initially experienced greater weight loss, the differences were not statistically significant at later follow-up assessments.
These findings build upon earlier research. A study published in February 2026 evaluated 120 postmenopausal women receiving tirzepatide (The Role of Menopause Hormone Therapy in Modulating Tirzepatide-Associated Weight Loss, 2026). Women using hormone therapy lost an average of 19.2% of their starting body weight, compared with 14.0% among women not receiving hormone therapy.
Similarly, a 2024 study involving 106 postmenopausal women receiving semaglutide found that women using hormone therapy lost approximately 16% of their starting body weight after one year, compared with 12% among those not using hormone therapy (Weight Loss Response to Semaglutide in Postmenopausal Women With and Without Hormone Therapy Use, 2024).
Although these findings are promising, they do not prove that hormone therapy itself was responsible for the additional weight loss. Other factors may have contributed, and further clinical trials are needed to confirm whether combining these treatments offers a meaningful advantage.
How Do Estrogen and Progesterone Influence Hunger and Appetite?
Estrogen and progesterone do much more than regulate the menstrual cycle. Both hormones influence how the body regulates hunger, fullness, and energy balance.
Estrogen, particularly estradiol, generally has an appetite-suppressing effect. It acts on estrogen receptors within the hypothalamus, a region of the brain involved in regulating hunger and satiety. Estrogen also interacts with gastrointestinal hormones that help signal fullness after eating.
Progesterone’s role is more complex. It may counteract some of estrogen’s appetite-suppressing effects, which may help explain why women commonly experience increased hunger or food cravings during the second half of their menstrual cycle.
Interestingly, GLP-1 medications act on some of the same appetite-regulating pathways influenced by estrogen. Early laboratory research suggests that estrogen and GLP-1 signaling may interact, potentially enhancing the brain’s response to signals of fullness.
This provides a possible biological explanation for the greater weight loss observed among women receiving both treatments. However, whether estrogen directly enhances GLP-1 medication effectiveness in humans remains uncertain.
Another possibility is that hormone therapy improves menopausal symptoms, particularly hot flashes, night sweats, and sleep disturbances. Improvements in sleep and overall well-being may indirectly support healthier eating patterns, physical activity, and weight management.
Why Does Body Fat Accumulate Around the Abdomen During Menopause?
One of the most noticeable changes during menopause is a shift in where the body stores fat.
Before menopause, estrogen helps favor fat storage in the subcutaneous tissue around the hips, thighs, and buttocks, contributing to a more pear-shaped body fat distribution.
Estrogen regulates fat-cell activity through receptors in adipose tissue, influencing how fat is stored and released throughout the body. It also helps limit excessive accumulation of visceral fat, the fat surrounding internal abdominal organs.
As estrogen levels decline during menopause, these regulatory effects change. Fat accumulation increasingly favors the abdominal region, contributing to a shift from a predominantly pear-shaped to a more central fat distribution.
This distinction matters because visceral fat is metabolically different from fat stored around the hips and thighs. Excess visceral fat is associated with increased inflammation, insulin resistance, and a greater risk of type 2 diabetes and cardiovascular disease.
However, changes in body composition during menopause are multifactorial. Aging, loss of muscle mass, reduced energy expenditure, sleep disturbances, physical activity, and dietary habits all contribute to changes in body weight.
Although hormone therapy may have favorable effects on fat distribution in some women, it does not reliably produce significant weight loss or reverse all the metabolic changes associated with aging.
Why Do Some Women Notice Weight Gain After Starting Hormone Therapy?
Although estrogen influences appetite and fat distribution, this does not mean that starting hormone therapy automatically leads to weight loss.
Some women experience temporary bloating, breast tenderness, or fluid retention after initiating hormone therapy. These changes may increase the number on the scale without necessarily reflecting an increase in body fat.
Additionally, women often begin hormone therapy during a period of life when weight and body composition are already changing. This can make it difficult to distinguish changes associated with treatment from those occurring naturally during the menopause transition.
Large clinical studies have not demonstrated that menopausal hormone therapy causes significant additional weight gain on average. However, individual experiences vary, and persistent weight changes deserve a more comprehensive evaluation.
The key distinction is that hormone therapy can influence fat distribution and metabolic regulation without necessarily producing meaningful changes in overall body weight.
What Does This Mean for Women Navigating Menopause?
The emerging research highlights an important connection between reproductive hormones and metabolic health.
Women who are appropriate candidates for both menopausal hormone therapy and obesity medications may benefit from receiving both treatments, although each should be prescribed based on its own established medical indications.
Menopausal hormone therapy remains an effective treatment for bothersome menopausal symptoms and can help prevent bone loss in appropriately selected women. However, weight gain alone is not an indication for hormone therapy.
For now, the available evidence suggests a potential relationship between hormone therapy and improved response to certain GLP-1-based medications, but more research is needed before this finding changes clinical practice.
As our understanding of estrogen, appetite regulation, and metabolic health continues to evolve, these discoveries may help guide more personalized approaches to obesity treatment during menopause and beyond.
If you’re navigating perimenopause or menopause and struggling with weight gain, an individualized approach can help you better understand your options. Schedule an appointment with our team to discuss your metabolic health and available treatment options.
